How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

被引：0
|
作者：
Zheng, Lucy [1 ]
Zheng, X. Long [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd,Delp 5016, Kansas City, KS 66160 USA
来源：
ANNALS OF BLOOD | 2023年 / 8卷
关键词：
PLASMA-EXCHANGE; REFRACTORINESS; MORTALITY; ADAMTS13;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
    Zheng, Lucy
    Zheng, X. Long
    ANNALS OF BLOOD, 2023, 8
  • [2] Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura
    Reti, Marienn
    Sinkovits, Gyorgy
    Varkonyi, Andrea
    Kiraly, Agnes
    Farkas, Zita
    Bogsch, Luca
    Icleanu, Andreea-Adela
    Masszi, Tamas
    Valyi-Nagy, Istvan
    Prohaszka, Zoltan
    Remenyi, Peter Pal
    BLOOD, 2023, 142
  • [3] Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab
    Tse, Brandon
    Buchholz, Megan
    Pavenski, Katerina
    BMJ CASE REPORTS, 2021, 14 (08)
  • [4] Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
    Agosti, Pasquale
    Leo, Pasqualina De
    Capecchi, Marco
    Ferrari, Barbara
    Mancini, Ilaria
    Gattillo, Salvatore
    Trisolini, Silvia Maria
    Rinaldi, Erminia
    Podda, Gian Marco
    Prezioso, Lucia
    Salutari, Prassede
    Facchini, Luca
    Caramazza, Domenica
    Tolomelli, Giulia
    Artoni, Andrea
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (06)
  • [5] Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
    Scully, M.
    Cataland, S. R.
    Peyvandi, F.
    Coppo, P.
    Knobl, P.
    Hovinga, J. A. Kremer
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 335 - 346
  • [6] Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod, Adrien
    Veyradier, Agnes
    Coppo, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (01) : 58 - 67
  • [7] CRYOSUPERNATANT SHOULD BE USED IN THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA
    ROCK, G
    SUTTON, D
    BENNY, B
    SHUMAK, K
    NAIR, R
    BLOOD, 1994, 84 (10) : A246 - A246
  • [8] Caplacizumab for the Treatment of acquired thrombotic thrombocytopenic Purpura (aTTP)
    Oezcan, F.
    NEPHROLOGE, 2019, 14 (06): : 470 - 472
  • [9] Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura
    Reid, Justin H.
    Durant, Karin M.
    Chen, Sheh-Li
    Perissinotti, Anthony J.
    King, Richard
    Khoriaty, Rami
    Marini, Bernard L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (07) : 1695 - 1702
  • [10] Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment
    le Besnerais, Maelle
    Veyradier, Agnes
    Benhamou, Ygal
    Coppo, Paul
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1127 - 1134
12345